ABX464-101

September 21, 2020September 21, 2020

ABX464 Effective at Keeping UC Patients in Remission Over Time, Data Show

News, Ulcerative colitis

ABX464, Abivax’s treatment candidate for ulcerative colitis (UC), continues to be safe and effective over time at keeping patients with moderate-to-severe UC in clinical remission, according to two-year data from a ... Read more

March 18, 2020March 18, 2020

Data from Abivax Trial Testing ABX464 Anti-inflammatory for UC Expected by Year’s End

News

Top-line data from an international Phase 2b clinical trial evaluating ABX464, Abivax’s lead therapeutic candidate for moderate-to-severe ulcerative colitis (UC), are expected later this year, according to the company’s financial ... Read more

January 8, 2018January 8, 2018

Belgium Approves Extension Trial of Abivax’s Ulcerative Colitis Therapy

News

Regulators in Belgium have approved Abivax’s request for a long-term extension of the company’s ongoing Phase 2a trial of ABX464 as a treatment for ulcerative colitis. It said it expects approvals from ... Read more

November 21, 2017

First Patient Enrolls in Phase 2 Trial of ABX464, Potential Ulcerative Colitis Treatment

News

A first patient has been enrolled in a proof-of-concept clinical trial of ABX464 as a possible treatment for people with moderate-to-severe active ulcerative colitis, its developer, Abivax, announced in a press release. The patient ... Read more